His scientific interests lie mostly in Psychiatry, Schizophrenia, Cognition, Clinical psychology and Psychosis. His Positive and Negative Syndrome Scale study in the realm of Schizophrenia interacts with subjects such as Context. His Cognition study incorporates themes from Schizophrenia, Research design and Psychometrics.
The various areas that Richard S.E. Keefe examines in his Clinical psychology study include Longitudinal study, Clinical trial, Neuropsychology, Mental health and Cohort. His studies deal with areas such as Vigilance, Cognitive disorder, Intelligence quotient and Agnosia as well as Psychosis. Richard S.E. Keefe combines subjects such as Quetiapine, Risperidone and First episode, Internal medicine with his study of Olanzapine.
The scientist’s investigation covers issues in Psychiatry, Cognition, Schizophrenia, Clinical psychology and Psychosis. Richard S.E. Keefe has researched Cognition in several fields, including Schizophrenia, Clinical trial and Developmental psychology, Psychometrics. In his research on the topic of Schizophrenia, Placebo is strongly related with Internal medicine.
His Clinical psychology study combines topics in areas such as Cognitive remediation therapy, Cognitive skill, Effects of sleep deprivation on cognitive performance, Cognitive test and Schizotypal personality disorder. His research integrates issues of Perception and Audiology in his study of Psychosis. His work investigates the relationship between Olanzapine and topics such as Risperidone that intersect with problems in Quetiapine and Perphenazine.
His primary areas of investigation include Cognition, Schizophrenia, Clinical psychology, Psychosis and Schizophrenia. His Cognition study contributes to a more complete understanding of Psychiatry. His work on Bipolar disorder as part of general Psychiatry study is frequently linked to Genome-wide association study, bridging the gap between disciplines.
The concepts of his Schizophrenia study are interwoven with issues in Neurocognitive, Placebo and Internal medicine. His Clinical psychology research integrates issues from Outpatient clinic, Cognitive test, Anxiety, Treatment response and Cohort. His biological study spans a wide range of topics, including Psychotherapist, Association, Emotion recognition and Audiology.
Richard S.E. Keefe mainly focuses on Cognition, Schizophrenia, Clinical psychology, Psychiatry and Clinical trial. His Cognition research is multidisciplinary, relying on both Physical therapy, Psychopathology and Cognitive decline. His study in the field of Positive and Negative Syndrome Scale also crosses realms of Degree.
His Clinical psychology research includes themes of Young adult, Neurocognitive, Consistency and Outpatient clinic. His Connectomics research extends to the thematically linked field of Psychiatry. His work in Clinical trial covers topics such as Cognitive test which are related to areas like Standard score, Audiology, Test and Cognitive Assessment System.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman;T. Scott Stroup;Joseph Patrick McEvoy;Joseph Patrick McEvoy;Marvin S. Swartz.
The New England Journal of Medicine (2005)
The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
Keith H. Nuechterlein;Michael F. Green;Robert S. Kern;Lyle E. Baade.
American Journal of Psychiatry (2008)
Persistent cannabis users show neuropsychological decline from childhood to midlife
Madeline H. Meier;Avshalom Caspi;Antony Ambler;Antony Ambler;Hona Lee Harrington.
Proceedings of the National Academy of Sciences of the United States of America (2012)
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Richard S.E Keefe;Terry E Goldberg;Philip D Harvey;James M Gold.
Schizophrenia Research (2004)
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe;Robert M. Bilder;Sonia M. Davis;Philip D. Harvey.
Archives of General Psychiatry (2007)
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph Patrick McEvoy;Jeffrey A. Lieberman;T. Scott Stroup;Sonia M. Davis.
American Journal of Psychiatry (2006)
Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria
Michael F. Green;Keith H. Nuechterlein;James M. Gold;M Deanna.
Biological Psychiatry (2004)
The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis
Richard S.E. Keefe;Susan G. Silva;Diana O. Perkins;Jeffrey A. Lieberman.
Schizophrenia Bulletin (1999)
Antipsychotic drug effects on brain morphology in first-episode psychosis
Jeffrey A. Lieberman;Jeffrey A. Lieberman;Gary D. Tollefson;Cecil Charles;Robert Zipursky.
Archives of General Psychiatry (2005)
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
Philip D. Harvey;Richard S.E. Keefe.
American Journal of Psychiatry (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: